Loss of SETD2‐mediated downregulation of intracellular and exosomal miRNA‐10b determines MAPK pathway activation and multidrug resistance in renal cancer

Abstract

AbstractSET domain‐containing 2 (SETD2) is the most frequently mutated gene among all the histone methyltransferases in clear cell renal cell carcinoma (ccRCC). Microarrays, RNA sequencing analysis and exosomes analysis of cellular supernatant were performed after transfection A498 cells with si‐SETD2 or siRNA of negative control. Chromatin immunoprecipitation and Luciferase reporter assay were conducted to evaluate the interaction between SETD2 and miR‐10b. Functional and drug experiments in vitro and in vivo were performed to verify the role of SETD2, miR‐10b and MAP4K4. The results showed that loss of SETD2 mediated downregulation of intracellular and exosomal microRNA‐10b. MAP4K4 were relevant to oncogenesis of ccRCC caused by loss of SETD2 and miR‐10b. SETD2 could directly target miR‐10b and regulate the expression of multidrug resistance (MDR)‐1 (P‐gp170) through JNK pathway, which was one of the downstream pathways of MAP4K4. The coordinated expression of SETD2/H3K36me3/miR‐10b/MAPKs/JNK/MDR pathway was revealed to the progression of ccRCC.